Shots:

• Athenex to receive $30M up front- ~$170M milestones and royalties on sales of licensed products in China- Hong Kong and Macao. Xiangxue to get exclusive license to develop & commercialize Athenex’s oral Paclitaxel- oral Irinotecan and Tirbanibulin ointment for the treatment of actinic keratosis (AK) in licensed territories
• The collaboration represents the expansion of their existing relationship on KX2-361 for brain tumors and TCR-T immunotherapy and expands Xiangxue’s novel drug portfolio into a pipeline comprising two P-III & one P-I candidate- one with POC data
• The collaboration emphasizes the global value of Athenex’s advancing pipeline and platform technologies. Additionally- Xiangxue plans to expand its marketing and sales infrastructure to focus on China to capture the full potential of licensed products

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image:  Athenex